The p53 mutant BON1 and NCI-H727 cells are resistant to NVP-CGM097, but when combined with 5-fluorouracil, it exerts a potential therapeutic effect on neuroendocrine tumors by increasing the expression of p53 and p21 [93]. Here, TP53 is linked to neuroendocrine neoplasm.